Artrya AI Tech targets hidden heart disease risk - ASX SMIDcaps Conference

Artrya Limited CEO & Co-Founder John Konstantopoulos talked with Jonathan Jackson from Proactive at the Small and Mid-Cap Conference about the company’s AI-driven approach to transforming heart disease detection and diagnosis. He explained that heart disease remains the leading cause of death globally, often going undetected until it is too late. Konstantopoulos highlighted a key issue in current diagnostics, stating, “what is really causing the heart attack is a soft inflammation that forms early on and doctors don’t see it.” Artrya’s solution uses artificial intelligence to analyse coronary angiograms and identify inflammatory plaque in real time, enabling earlier and more precise risk assessment without invasive procedures. The company is also leveraging AI to simulate blood flow non-invasively, further enhancing diagnostic capabilities. A major focus for Artrya is its Sapphire study, which aims to demonstrate how earlier detection—particularly in asymptomatic patients—could shift the standard of care toward prevention. The study also serves as a commercial pathway, helping the company engage major US hospital systems and accelerate contract conversions. Konstantopoulos outlined a significant market opportunity, with 4.5 million CT scans conducted annually and a total addressable market valued at $4.4 billion. With cloud-based software delivering margins above 90%, the company is positioning itself for scalable growth. Near-term milestones include study results, regulatory clearances, and expanding its US customer base. #proactiveinvestors #asx #aya #OTC #ayauf #Artrya #HeartDisease #AIHealthcare #MedTech #Cardiology #AIinMedicine #HealthcareInnovation #MedicalAI #Diagnostics #ASX #Investing #Biotech #DigitalHealth #PreventiveMedicine #HealthcareTechnology